In late 2008, bluetongue virus (BTV) serotype 6 (BTV-6), which had never occurred in 23
Europe before, was first detected in the Netherlands and Germany. While the origin of 24 the virus remains unknown, the prevalence of infections in cattle was investigated in a 25 virological (N= 28,658) and serological (N= 2,075) field survey in Lower Saxony, 26
where 45 cases confined to the district Grafschaft Bentheim were found. Blood from 27 affected animals was used for the experimental infection of three cattle with different 28 BTV antibody status, leading to sustained viraemia in one animal naïve for BTV. Of 29 two animals that had detectable antibodies against BTV serotype 8, one became 30 transiently infected and seroconverted for BTV-6 while the other did not react. In facility of the FLI on Insel Riems, where they were confirmed to be free of circulating 112 BTV genome by real-time RT-PCR analysis of blood samples (Toussaint et al., 2007) . 113
They came from a region where BTV has never been reported. They were purchased as 114 immunised against BTV-8 with two doses of an inactivated vaccine (BTVPUR® AlSap 115 8, Merial S.A.S., Lyon, France) but displayed different levels of BTV-specific 116 antibodies (Table I ). The calves had been vaccinated with a gE-deleted BHV-1 marker 117 vaccine. They had detectable antibodies against BVDV, and were negative for BVDV 118
antigen. 119
On day 0 of the study, the animals were inoculated intravenously and subcutaneously 120 (multiple sites in the shoulder region) with BTV-6 positive blood pooled from samples 121 submitted to the NRL. None of the samples contained detectable BTV-8 RNA (data not 122 shown). Packed blood cells of the inoculum had been repeatedly washed with 123 phosphate-buffered saline solution (PBS) and then ultrasonically disrupted. The blood 124 preparation was tested free of bacterial contamination and it had a threshold cycle (C t ) 125 value of 26.87 in the BTV-6 specific real-time RT-PCR (Hoffmann et al., 2009b) . 126
After inoculation, blood samples were taken at regular intervals. Blood was drawn by 127 jugular puncture and collected in tubes containing potassium EDTA or clot activator, 128 respectively (Monovette, Sarstedt, Nümbrecht, Germany). Samples were stored at 4 °CA c c e p t e d M a n u s c r i p t Total RNA from whole blood samples was extracted manually using a commercial kit 149 (QIAamp Viral RNA Mini Kit, QIAGEN, Hilden, Germany). The amount of BTV 150 genome in the samples was determined using the "pan-BTV" assay by Toussaint et al. 151 (2007) and the in-house BTV-6 and BTV-8 assays that had also been used for the field 152 samples (Hoffmann et al., 2009b) . The "pan-BTV" assay amplifies a highly conserved M a n u s c r i p t was 96% for female cattle, 69% for sheep and 47% for goats. In the 2,075 sera tested at 196 IZSAM, only antibodies against BTV-8 and -6 were found (Table III) (Table I) . After 207 inoculation with BTV-6, two animals (calves 605 and 588) displayed measurable virus 208 replication (as detected by real-time RT-PCR, Table IV) and subsequently  209 seroconverted for BTV-6 after two and three weeks, respectively, together with a 210 marked increase in group-specific antibodies (Table I) . Calf 607 failed to react both in 211 the real-time RT-PCR (data not shown) and by serology. 212
Calf 588 was only transiently infected and had already fully cleared the virus four 213 weeks after infection, but the viraemia in calf 605 lasted over six weeks (Table IV) . The 214 animal remained BTV-6-positive in the real-time RT-PCR for over 100 days until the 215 end of the study period. BTV-8 was not detected in any animal (data not shown). 216
Between days 5 and 9 after infection, calf 605 had a slightly elevated body temperatureM a n u s c r i p t 11 and calf 588 showed a similar increase in temperature from day 10 to 12 (data not 218 shown), while no other clinical signs could be observed. 
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